Q4 2022 Results

Company overview Financial review 2023 priorities Appendix As a pure-play Innovative Medicines company, New Novartis is uniquely positioned to leverage its scale, strengths and expertise STRATEGY Novartis is on track to become a pure-play Innovative Medicines company Simplified organizational model allowing for greater focus, leveraging scale and expertise Illustrative Large diversified pharma Divested consumer health JV Jun 2018 Spun Alcon Apr 2019 Announced planned Sandoz spin-off¹ Aug 2022 New Novartis Exited Roche stake 100% Nov 2021 Innovative Medicines 1. Company filings and FactSet. 2. Median P/E (Bloomberg, current year). 6 Investor Relations | Q4 2022 Results Total company revenue¹ N J Large pure-play pharma H New Novartis >$40bn Mid-size diversified M pharma K Diversified pharma² Median P/E 13x Mid-size pure-play pharma A B E D <100% Pharma contribution to total sales1 Pure-play pharma² Median P/E 20x ✓ NOVARTIS | Reimagining Medicine

View entire presentation